Results 291 to 300 of about 44,151 (306)

Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis

Journal of Clinical Gastroenterology, 2019
Supplemental Digital Content is available in the text. Background: Left ventricular diastolic dysfunction (LVDD) refers to impaired cardiac diastolic relaxation and may be improved by targeted heart rate reduction (THR).
Madhumita Premkumar, D. Rangegowda, Tanmay Vyas, Jelen S. Khumuckham, S. Shasthry, S. Thomas, Ritu Goyal, G. Kumar, S. Sarin   +8 more
semanticscholar   +1 more source

Pharmacological characteristics of the stereoisomers of carvedilol

European Journal of Clinical Pharmacology, 1990
The racemic compound carvedilol possesses two complementary pharmacological effects, vasodilation and beta-blockade. The R- and S-enantiomers of carvedilol and the racemate were investigated with respect to the beta-blocking, vasodilating, and hypotensive actions.
W. Bartsch, K. Strein, Ulrich Martin, B. Müller-Beckmann, Lothar Kling, E. Böhm, G. Sponer, H. O. Borbe   +7 more
openaire   +3 more sources

Effects of carvedilol on renal function

European Journal of Clinical Pharmacology, 1990
A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function. Acute administration of a single dose of 50 mg carvedilol reduced systolic and diastolic blood pressure without inducing reflex ...
openaire   +3 more sources

Carvedilol

DMW - Deutsche Medizinische Wochenschrift, 2009
W, Antepohl, S, Herzig, M, Böhm
openaire   +2 more sources

Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol

Expert Opinion on Pharmacotherapy, 2006
Carvedilol is a third-generation beta(1)- and beta(2)-blocker that also possesses alpha(1)-adrenergic-blocking properties. This compound has: i) shown superior efficacy to certain other beta-blockers in heart failure, ii) can improve myocardial function (e.g., in myocardial infarction) and iii) is the only beta-blocker shown to significantly reduce ...
openaire   +3 more sources

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.

Journal of the American College of Cardiology, 2018
M. Avila, S. Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, V. O. Rigaud, M. H. Higuchi-Dos-Santos, L. Hajjar, R. Kalil Filho, P. Hoff, Marina Sahade, M. S. Ferrari, Romulo Leopoldo de Paula Costa, M. Mano, Cecilia Beatriz Bittencourt Viana Cruz, M. C. Abduch, Marco Stephan Lofrano Alves, G. Guimãraes, V. Issa, M. Bittencourt, E. Bocchi   +20 more
semanticscholar   +1 more source

Impact of the mucoadhesive lyophilized wafer loaded with novel carvedilol nano-spanlastics on biochemical markers in the heart of spontaneously hypertensive rat models

Drug Delivery and Translational Research, 2020
N. Sallam, R. Sanad, Mahgoub M Ahmed, El-Sayed Khafagy, M. Ghorab, S. Gad   +5 more
semanticscholar   +1 more source

Improvement of oral bioavailability of carvedilol by liquisolid compact: optimization and pharmacokinetic study

Drug Delivery and Translational Research, 2020
Mimansa Jhaveri, Anroop B Nair, Jigar N. Shah, S. Jacob, Vimal Patel, T. Mehta   +5 more
semanticscholar   +1 more source

Carvedilol

2016
openaire   +1 more source

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

The Lancet, 2003
P. Poole‐Wilson, K. Swedberg, J. Cleland, A. Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W. Remme, C. Torp-Pedersen, A. Scherhag, A. Skene   +12 more
semanticscholar   +1 more source